Advertisement

Milrinone Injection

[17 July 2014]

Products Affected - Description

Milrinone injection, Bedford
1 mg/mL, 10 mL vial (NDC 55390-0019-10)
1 mg/mL, 20 mL vial (NDC 55390-0020-10)
1 mg/mL, 50 mL vial (NDC 55390-0021-10)
0.2 mg/mL, 100 mL premixed bags (NDC 55390-0078-01)
0.2 mg/mL, 200 mL premixed bags (NDC 55390-0079-01)
 
Milrinone injection, Fresenius Kabi (formerly APP)
1 mg/mL, 10 mL vial (NDC 63323-0617-10)
1 mg/mL, 20 mL vial (NDC 63323-0617-20)
 
Milrinone injection, Hospira
0.2 mg/mL, 100 mL premixed bags (NDC 00409-2776-23)
 
Milrinone injection, West-Ward 
0.2 mg/mL, 100 mL premixed bags (NDC 00143-9719-10)
1 mg/mL, 20 mL vial (NDC 00143-9709-10)

Reason for the Shortage

  • Fresenius Kabi (formerly APP) states the reason for the shortage was increased demand for the product.
  • West-Ward acquired Baxter’s milrinone injection vials in May 2011.
  • West-Ward states the shortage is due to manufacturing delays.
  • Baxter had milrinone premixed bags on shortage due to increased demand.
  • Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
  • Apotex, Bioniche, and Teva discontinued milrinone 1 mg/mL vials.
  • Sanofi-Aventis discontinued Primacor injection.

Available Products

Milrinone injection, Baxter
0.2 mg/mL, 100 mL premixed bags (NDC 00338-6010-48)
0.2 mg/mL, 200 mL premixed bags (NDC 00338-6011-37)
 
Milrinone injection, Fresenius Kabi
1 mg/mL, 50 mL vial (NDC 63323-0617-50)

 
Milrinone injection, Hospira
0.2 mg/mL, 200 mL premixed bags (NDC 00409-2776-02)
 
Milrinone injection, West-Ward
0.2 mg/mL, 200 mL premixed bags (NDC 00143-9718-10)
1 mg/mL, 10 mL vial (NDC 00143-9710-10)
1 mg/mL, 50 mL vial (NDC 00143-9708-01)

Estimated Resupply Dates

  • Bedford has milrinone 1 mg/mL 10 mL and 20 mL vials and 0.2 mg/mL 100 mL and 200 mL premixes on back order and the company cannot estimate a release date. Milrinone 1 mg/mL 50 mL vials are on back order and the company cannot estimate a release date; check with wholesalers for availability of the 50 mL vials.
  • Hospira has milrinone 0.2 mg/mL 100 mL premixed bags on back order and the company estimates a release date in July 2014.
  • Fresenius Kabi has milrinone 1 mg/mL 10 mL and 20 mL vials on back order and the company estimates a release date in early-September 2014.
  • West-Ward has milrinone 1 mg/mL 20 mL vials on allocation. Milrinone 0.2 mg/mL 100 mL premixed bags are on back order and the company estimates a release date of late-July to early-August 2014.

Related Shortages

Updated

July 17, 2014; July 14, 2014; July 2, 2014; May 30, 2014; May 19, 2014; April 30, 2014; April 16, 2014; April 1, 2014; March 11, 2014; March 7, 2014; February 14, 2014; February 3, 2014; January 21, 2014; December 12, 2013; November 26, 2013; November 15, 2013; October 24, 2013; September 12, 2013; August 26, 2013; August 14, 2013; July 9, 2013; July 3, 2013; June 20, 2013; May 8, 2013; April 19, 2013; February 7, 2013; December 12, 2012; November 15, 2012; November 7, 2012; October 2, 2012; September 14, 2012; July 26, 2012; July 9, 2012; June 21, 2012; June 4, 2012; May 25, 2012; April 27, 2012; March 22, 2012; March 2, 2012; February 17, 2012; January 13, 2012; January 11, 2012; March 7, 2011, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement